Hier finden Sie grundlegende Angaben zu klinischen Studien des Comprehensice Cancer Centers Mainfranken (CCC MF)
Filter aktiv
Seite 1 - Studien 1 bis 9 von insgesamt 9
- Rekrutierung läuftA Phase III, Double-blind, Randomised, Placebo-Controlled, International Study to assess the Efficacy and Safety of Adjuvant Osimertinib versus Placebo in Participants with EGFR mutation-positive Stage IA2-IA3 Non-small Cell Lung Cancer, following Complete Tumor Resection ( ADAURA2 )Molekulare Marker
- Rekrutierung läuftRadiation during Osimertinib Treatment: a Safety and Efficacy Cohort studyMolekulare Marker
- Rekrutierung läuft
A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First‑line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (D926NC00001; AVANZAR)
- Rekrutierung läuftFirst Line Ipilimumab+Nivolumab Combined with two cycles of Chemotherapy in NSCLC [FINN]
- Rekrutierung läuftA Randomized, Double-blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) ParticipantsMolekulare Marker
- Rekrutierung läuftInterventional Platform study investigating the impact of digital health solutions on health outcomes and health care resource utilization in participants receiving systemic treatment in clinical practice (ORIGAMA)Molekulare Marker
- Rekrutierung läuftA Phase III, double-blind, placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy (PACIFIC-9)
- Rekrutierung läuft
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer [CR109264]
Molekulare Marker - Rekrutierung läuftPANORAMA - Real World Molecular Testing, Treatment Patterns, and Clinical Outcomes in Patients With EGFR Mutation-Positive Locally Advanced or Advanced NSCLCMolekulare Marker